Tech Company Financing Transactions
Paradox Immunotherapeutics Funding Round
Symbiosis participated in a $10 million venture round for Paradox Immunotherapeutics. The round was announced on 2/25/2025.
Transaction Overview
Company Name
Announced On
2/25/2025
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its therapeutic pipeline through advancements in multiple indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 College St
Toronto, Ontario, M5G 1L5
Canada
Toronto, Ontario, M5G 1L5
Canada
Phone
Undisclosed
Website
Email Address
Overview
Paradox Immunotherapeutics is an pharmaceutical company developing immunotherapies for rare diseases using a proven-successful immunotherapy drug design platform. We design drugs that harness the body's own immune system to clear lethal deposits from affected organs and reverse organ damage. Our team has a successful history in designing drug candidates for amyloidosis and taking them from bench to bedside.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Natalie Galant
Chief Scientific Officer
Yulong Sun
Browse more venture capital transactions:
Prev: 2/25/2025: Bitwise Asset Management venture capital transaction
Next: 2/25/2025: Edera venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs